Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, rapid heart rate, shortness of breath, speech changes, weakness, and yellowish color to the skin (jaundice). Treatment includes surgery to remove the spleen and drugs that suppress the immune system, such as corticosteroids.
The Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
GC Biopharma CorpGuangzhou Institute of Biomedicine and Health
KM Biologics Co Ltd
MabTics
PlateletBio
TagCyx Biotechnologies
Takeda Pharmaceutical Co Ltd
TargED Biopharmaceuticals BV
Table of Contents
Table
Figures
Frequently asked questions